A novel framework categorizes pharmacological agents that improve myocardial performance into calcitropes, myotropes, and mitotropes based on their distinct mechanisms of action.
The term "inotrope" is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to improve cardiac performance. Thus, "inotropy" does not sufficiently describe the range of potential novel pharmaceutical products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Novel chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms and clinical outcomes.
Psotka et al. (Wed,) conducted a review in Low cardiac output with cardiogenic shock. Pharmacological agents improving myocardial performance (calcitropes, myotropes, mitotropes) was evaluated. A novel framework categorizes pharmacological agents that improve myocardial performance into calcitropes, myotropes, and mitotropes based on their distinct mechanisms of action.